Treatment of Waldenstrom’s Macroglobulinemia With Thalidomide

Dimopoulos, Meletios A.; Zomas, Athanassios; Viniou, Nora; Grigoraki, Vassiliki; Galani, Eleni; Matsouka, Charis; Economou, Olga; Anagnostopoulos, Nikolaos; Panayiotidis, Panayiotis

doi:10.1200/jco.2001.19.16.3596

Cited by 113 publications

(47 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During recent years, combination therapies with rituximab have resulted in good overall response rates but low complete response rates [23,24]. Newer therapies, including thalidomide and bortezomib have shown encouraging results; however, they were introduced during the last calendar period of this study and may have only a marginal effect on survival in this study [25][26][27][28][29]. Studies evaluating the effect of autologous stem cell transplantation in LPL/WM have been promising with low toxicities and high response rates [5,[30][31][32][33][34].…”

Section: Discussionmentioning

confidence: 86%

Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

et al. 2012

View full text Add to dashboard Cite

1980-1985, 1986-1990, 1991-1995, 1996-2000, and 2001-2005, respectively. Improvement in 1-and 5-year relative survival was found in all age groups and for LPL and WM separately. Patients with WM had lower excess mortality compared to LPL (EMRR 5 0.38; 95% CI 0.30-0.48). Older age at diagnosis was associated with a poorer survival (P < 0.001). Taken together, we found a significant improvement in survival in LPL/WM over time. Despite this progress, new effective agents with a more favourable toxicity profile are needed to further improve survival in LPL/ WM, especially in the elderly. Am. J. Hematol. 88:60-65, 2013. V

show abstract

Section: Discussionmentioning

confidence: 86%

Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Thalidomide has been evaluated for the therapy of other plasma cell proliferative disorders like Waldenström's Macroglobulinemia (WM) [46] and Systemic amyloidosis [47] (Table 3). It has also been evaluated in the therapy of acute myelogenous leukemia (AML) [48] where the authors also observed a significant decrease in the microvessel densities in the responding patients treated with thalidomide, which was accompanied by declining plasma levels of bFGF.…”

Section: Multiple Myeloma and Other Hematological Malignanciesmentioning

confidence: 99%

Thalidomide as an anti‐cancer agent

Kumar

Witzig

Rajkumar

2002

J Cellular Molecular Medi

View full text Add to dashboard Cite

Thalidomide is a glutamic acid derivative initially introduced as a sedative hypnotic nearly forty years ago. It was withdrawn following numerous reports linking it to a characteristic pattern of congenital abnormalities in babies born to mothers who used the drug for morning sickness. It has gradually been re-introduced into clinical practice over the past two decades, albeit under strict regulation, since it was found to be useful in the management of erythema nodosum leprosum and HIV wasting syndrome. Recognition of its anti-angiogenic effect led to its evaluation in the treatment of various malignancies, where angiogenesis has been shown to play an important role. Numerous clinical trials done over the past four years have confirmed the significant anti-myeloma activity of this drug. It has also shown promise in preliminary trials in the treatment of a variety of different malignant diseases. The mechanisms of its antineoplastic effects continue to be the focus of ongoing research. It has become clear that even though its anti angiogenic effects play a significant role in the anti-tumor activity, there are other properties of this drug which are responsible as well. It also possesses anti-TNF alpha activity, which has led to its evaluation in several inflammatory states. In this concise review, we briefly describe the historical background and pharmacological aspects of this drug. We have concisely reviewed the current knowledge regarding mechanisms of its anti-neoplastic activity and the results of various clinical trials in oncology. Keywords:

show abstract

“…Dimopoulos and colleagues [71] reported on 20 patients treated with thalidomide as a single agent at a median dose of 200 mg/day. Five of 20 patients achieved a 50% reduction in serum monoclonal IgM protein.…”

Section: Thalidomidementioning

confidence: 99%